Stockscreener 앱 받기
45.94
0.48%
0.22
시간 외 거래:
46.35
0.41
+0.89%
전일 마감가:
$45.72
열려 있는:
$46.2
하루 거래량:
6.05M
Relative Volume:
0.73
시가총액:
$18.22B
수익:
$1.94B
순이익/손실:
$-2.82B
주가수익비율:
-6.3263
EPS:
-7.2617
순현금흐름:
$-2.08B
1주 성능:
-13.07%
1개월 성능:
-9.57%
6개월 성능:
+69.15%
1년 성능:
+60.97%
1일 변동 폭
$45.75
$47.94
1주일 범위
$44.62
$53.49
52주 변동 폭
$22.28
$59.55
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
45.94 | 18.70B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Moderna (MRNA) Prepares for Earnings Amid Revenue Challenges - GuruFocus
Moderna Q1 preview: revenue rebound in focus as losses persist (MRNA:NASDAQ) - Seeking Alpha
Vanguard Capital Management (MRNA) reports 25.9M-share stake (6.53%) - Stock Titan
Moderna in the spotlight: Can pipeline offset earnings decline? By Investing.com - Investing.com Australia
How Will Moderna Stock React To Its Upcoming Earnings? - Trefis
Moderna Stock 5-Day Losing Spree: Stock Falls 18% - Trefis
Discipline and Rules-Based Execution in MRNA Response - Stock Traders Daily
mRNA Treatment Market 2026 | Argos Therapeutics, Inc., CureVac AG, ethris GmbH, Moderna, Inc., Tiba Biotech etc. - openPR.com
Pfizer, BioNTech Defeat Moderna COVID Jab Patent - Law360
Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026 - Yahoo Finance
Leading Companies Fueling Growth and Innovation in the Spikevax Market - openPR.com
Research Analysts Issue Forecasts for Moderna Q1 Earnings - MarketBeat
Salesforce Says Moderna Selects Agentforce Platform to Consolidate Commercial Operations - Moomoo
AACR 2026: Combo therapies by Moderna, Marengo show promise in skin, breast cancer - BioSpace
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect - Yahoo Finance
Is Moderna (MRNA) Pricing Make Sense After 77% One-Year Surge And DCF Signal? - Yahoo Finance
Moderna Hit With Suit Over CureVac COVID Patents - Law360
Moderna wins full FDA approval for COVID shot in children - MSN
CureVac Patent Suit Targets Moderna’s Spikevax Covid-19 Shots - Bloomberg Law News
Moderna shares dip amid rising selling pressure - Traders Union
Which Is the Better iShares ETF for Small-Cap Value Investing, ISCV or IWN? - The Motley Fool
Moderna, Inc. (MRNA) Stock Analysis: Navigating A 52-Week High Amidst Revenue Decline - DirectorsTalk Interviews
Moderna, Inc. (NASDAQ:MRNA) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Has $4.12 Million Position in Moderna, Inc. $MRNA - MarketBeat
M&T Bank Corp Acquires 240,400 Shares of Moderna, Inc. $MRNA - MarketBeat
MRNA Price Today: Moderna, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate - Eagle-Tribune
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 - Cadillac News
CureVac sues Moderna over mRNA vaccine patents - Investing.com
Moderna shares slide as traders digest recent EU vaccine clearance and refocus on funding/earnings overhangs - Quiver Quantitative
CureVac sues Moderna over mRNA vaccine patents By Investing.com - Investing.com Canada
Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
MRNA Technical Analysis | Trend, Signals & Chart Patterns | MODERNA INC (NASDAQ:MRNA) - ChartMill
Moderna (MRNA) Expected to Announce Earnings on Friday - MarketBeat
Moderna, Inc. (MRNA) Presents at ESCMID Global 2026Slideshow (NASDAQ:MRNA) 2026-04-23 - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
What does smart money think about Moderna (MRNA) stock (+1.11%) 2026-04-22Social Buzz - Cổng thông tin điện tử tỉnh Lào Cai
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
COVID vaccine report on cutting hospital visits blocked from publication in CDC journal - Seeking Alpha
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial - Healthcare Dive
European Commission Approves MRNA's COVID-19-Influenza Combo Shot - Yahoo Finance
Moderna starts late-stage trial for bird flu vaccine - Seeking Alpha
Analyst recommendations: Meta, Amazon, Booking, Goldman Sachs, Moderna… - marketscreener.com
Moderna : ESCMID 2026 (mRNA-1273 & mRNA-1283 Effectiveness and safety of variant updated Covid vaccines) - marketscreener.com
Amid US ordeal, Moderna wins EU approval for flu/COVID-19 combo shot - BioSpace
Moderna Inc. stock (US60770K1034): Does its mRNA pivot beyond COVID now unlock sustainable growth? - AD HOC NEWS
Moderna Inc. (MRNA)Announces Accepted Oncology Clinical Data Presentations at 2026 ASCO Annual Meeting, Schedules Concurrent Investor WebcastFloat Short - UBND thành phố Hải Phòng
Moderna Inc. (MRNA) Secures European Commission Marketing Authorization for World’s First Combined Influenza-COVID mRNA Vaccine mCOMBRIAXCost Structure - UBND thành phố Hải Phòng
Moderna to Present at Upcoming Conferences in May 2026 - Investing News Network
Moderna (MRNA) Advances with Phase 3 Study of Influenza Vaccine - GuruFocus
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.67%
자본화:
|
볼륨(24시간):